Description

• General description: In contrast to Fmoc-Lys(biotin)-OH, this novel biotin-labeled amino acid has excellent solubility in DMF and other solvents used in Fmoc SPPS [1]. The PEG-spacer restricts hindrance between the peptide and avidin, leading to better biotin binding. Furthermore, the hydrophilic nature of the PEG minimizes non-specific interactions that can arise from the spacer group becoming buried in the hydrophobic pocket of proteins.For recent applications, please see [2,3,4]. Associated Protocols and Technical ArticlesCleavage and Deprotection Protocols for Fmoc SPPSBiotinylation Reagents for Peptide SynthesisLiterature references[1] B. Baumeister, et al. (2003) Biopolymers, 71, 339. [2] X. Zhou et al., (2004) J. Am. Chem. Soc., 126, 15656. [3] B. F. Gilmore, et al. (2006) Biochem. Biophys. Res. Commun,, 347, 373. [4] C. T. Archer, et al. (2005) Mol. BioSyst., 1, 366.
• Application: Unbiased peptoid combinatorial cell screen identifies plectin protein as a potential biomarker for lung cancer stem cells: Utilized Fmoc-Glu(biotinyl-PEG)-OH in the synthesis protocol for peptoid libraries, contributing to biomarker discovery in lung cancer research (AC Raymond et al., 2019). Identification of side arm-modified DOTA scaffolds as multi-site binding ligands for cancer cells over normal cells: Included Fmoc-Glu(biotinyl-PEG)-OH in a synthesis protocol to enhance biotinylated scaffold properties for selective cancer cell targeting (V Rustagi, DG Udugamasooriya, 2019). TANGO-inspired design of anti-amyloid cyclic peptides: Employed Fmoc-Glu(biotinyl-PEG)-OH in the synthesis of cyclic peptides aimed at studying amyloid protein interactions, crucial for Alzheimer′s disease research (X Lu, RM Murphy, 2016). Converting a weaker ATP-binding site inhibitor into a potent hetero-bivalent ligand by tethering to a unique peptide sequence derived from the same kinase: Used Fmoc-Glu(biotinyl-PEG)-OH in developing new kinase inhibitors with improved binding properties (SR Kedika, DG Udugamasooriya, 2018).
• Linkage: Replaces: 04-12-1250
• Analysis Note: Color (visual): white to slight yellow to beigeAppearance of substance (visual): powderIdentity (IR): passes testEnantiomeric purity: ≥ 99.5 % (a/a)Purity (TLC(CMA2)): ≥ 97 %Assay (HPLC, area%): ≥ 95.0 % (a/a)Solubility (0,2 mmol in 1 ml DMF): clearly solubleTo see the solvent systems used for TLC of Novabiochem® products please click here.
• Legal Information: Novabiochem is a registered trademark of Merck KGaA, Darmstadt, Germany